A novel mechanism of action for statins against diabetes-induced oxidative stress

Diabetologia

Volumn 50, Issue 4, 2007, Pages 874-880

  Vecchione, C ^a   Gentile, M T ^a   Aretini, A ^a   Marino, G ^a   Poulet, R ^a   Maffei, A ^a   Passarelli, F ^b   Landolfi, A ^a   Vasta, A ^a   Lembo, G ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atorvastatin; Diabetes; Oxidative stress; Rac 1

Indexed keywords

ADENOVIRUS VECTOR; ATORVASTATIN; FLUORESCEIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUTANT PROTEIN; P21 ACTIVATED KINASE; PEROXIDE; RAC1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VASCULAR DISEASE;

ANIMALS; ANTIOXIDANTS; AORTA; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; POLYISOPRENYL PHOSPHATES; PYRROLES; RAC GTP-BINDING PROTEINS;

EID: 33847606920     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0597-0     Document Type: Article

References (29)

1. King GL, Buzney SM, Kahn CR et al (1983) Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 71:974-979
2. Laakso M (1999) Hyperglycemia and cardiovascular disease in type II diabetes. Diabetes 48:937-942
3. Meigs JB, O'Donnell CJ, Tofler GH et al (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530-537
4. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
5. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767
6. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
7. Sakamoto K, Murata T, Chuma H, Hori M, Ozaki H (2005) Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol 25:327-333
8. Shinohara K, Shoji T, Kimoto E et al (2005) Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 12:205-210
9. Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS (2005) Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 54:2977-2982
10. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R; Heart Protection Study Collaborative Group (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 365:1779-1785
11. Beckman JA, Liao JK, Hurley S et al (2004) Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 95:217-223
12. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M (2002) Glucose increases endothelial-dependent superoxide formation in coronary arteries by NADPH oxidase activation: attenuation by the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 51:2648-2652
13. Kinsella BT, Erdman RA, Maltese WA (1991) Carboxyl-terminal isoprenylation of ras-related GTP binding proteins encoded by rac1, rac2 and ralA. J Biol Chem 266:9786-9794
14. Gorzalczany Y, Sigal N, Itan M, Lotan O, Pick E (2000) Targeting of Rac1 to the phagocyte membrane is sufficient for the induction of NADPH oxidase assembly. J Biol Chem 275:40073-40081
15. Vecchione C, Aretini A, Marino G et al (2006) Selective Rac-1 inhibition protects from diabetes-induced vascular injury. Circ Res 98:218-225
16. Burkart V, Wang ZQ, Radons J et al (1999) Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozotocin. Nat Med 5:314-319
17. Soriano FG, Virag L, Jagtap P et al (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113
18. Vecchione C, Fratta L, Rizzoni D et al (2002) Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation 105:1700-1707
19. Vecchione C, Patrucco E, Marino G et al (2005) Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3K. J Exp Med 201:1217-1228
20. Endres M, Laufs U (2004) Effects of statins on endothelium and signalling mechanisms. Stroke 35:2708-2711
21. Harris MB, Blackstone MA, Sood SG et al (2004) Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287:H560-H566
22. Mraiche F, Cena J, Das D, Vollrath B (2005) Effects of statins on vascular function of endothelin-1. Br J Pharmacol 144:715-726
23. Maack C, Kartes T, Kilter H et al (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108:1567-1574
24. Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412
25. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA (1996) Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97:22-28
26. Naka Y, Bucciarelli LG, Wendt T et al (2004) RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24:1342-1349
27. Diekmann D, Abo A, Johnston C, Segal AW, Hall A (1994) Interaction of Rac with p67phox and regulation of phagocytic NADPH oxidase activity. Science 265:531-533
28. Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW (1991) Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353:668-670
29. Vecchione C, Brandes RP (2002) Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91:173-179